Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Leases Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Notes Payables Operating Leases Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Neogenomics (NEO) Non-Current Deffered Revenue (2017 - 2018)

Neogenomics filings provide 2 years of Non-Current Deffered Revenue readings, the most recent being $1.2 million for Q3 2018.

On a quarterly basis, Non-Current Deffered Revenue changed N/A to $1.2 million in Q3 2018 year-over-year; TTM through Sep 2018 was $1.2 million, a N/A change, with the full-year FY2017 number at $283000.0, changed N/A from a year prior.
Non-Current Deffered Revenue hit $1.2 million in Q3 2018 for Neogenomics, up from $648000.0 in the prior quarter.
In the past five years, Non-Current Deffered Revenue ranged from a high of $1.2 million in Q3 2018 to a low of $283000.0 in Q4 2017.